MedTrace Logo

Evaluation of Patiromer in Heart Failure Patients

NCT00868439 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-06-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.

Conditions

Interventions

DRUG

patiromer

Active investigational drug

DRUG

placebo

placebo

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • Relypsa, Inc.

    lead INDUSTRY

Principal Investigators

  • Director Clinical Operations · Relypsa, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-11-30
Completion
2009-12-31

Countries

  • United States
  • Czechia
  • Georgia
  • Germany
  • Poland
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00868439 on ClinicalTrials.gov